Pegylated Interferon-Alpha 2B
Lymphoma, Mantle-Cell
European Mantle Cell Lymphoma NetworkPhase 3Dormant
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 89/ 100
Competitive context
173 Active assets in the Lymphoma, Mantle-Cell cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
ETOPOSIDE Ruijin Hospital | Phase 4 | BBB |
CIS-DIAMMINEDICHLOROPLATINUM II National Cancer Institute (NCI) | Phase 4 | BBB |
Bendamustine Czech Lymphoma Study Group | Phase 2 | BBB |
VINCRISTINE SULFATE M.D. Anderson Cancer Center | Phase 2 | BBB |
Irinotecan University of Michigan Rogel Cancer Center | Phase 2 | BBB |
View all 50 →
Same molecule, other indications
Pegylated Interferon-Alpha 2B is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →